[go: up one dir, main page]

MX2013006184A - Compuestos de oxazol [5, 4-b]piridin-5-ilo y su uso para el tratamiento de cancer. - Google Patents

Compuestos de oxazol [5, 4-b]piridin-5-ilo y su uso para el tratamiento de cancer.

Info

Publication number
MX2013006184A
MX2013006184A MX2013006184A MX2013006184A MX2013006184A MX 2013006184 A MX2013006184 A MX 2013006184A MX 2013006184 A MX2013006184 A MX 2013006184A MX 2013006184 A MX2013006184 A MX 2013006184A MX 2013006184 A MX2013006184 A MX 2013006184A
Authority
MX
Mexico
Prior art keywords
oxazolo
pyridin
cancer
treatment
compounds
Prior art date
Application number
MX2013006184A
Other languages
English (en)
Inventor
Eva Maria Martin De La Nava
David Andrew Coates
Raymond Gilmour
Jose Alfredo Martin
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46162794&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013006184(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2013006184A publication Critical patent/MX2013006184A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención proporciona compuestos de oxazolo[5,4-b]piridin-5-ilo útiles en el tratamiento de cáncer.
MX2013006184A 2010-12-03 2011-11-17 Compuestos de oxazol [5, 4-b]piridin-5-ilo y su uso para el tratamiento de cancer. MX2013006184A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10382329 2010-12-03
US201161439151P 2011-02-03 2011-02-03
PCT/US2011/061099 WO2012074761A1 (en) 2010-12-03 2011-11-17 Oxazolo [5, 4 -b] pyridin- 5 -yl compounds and their use for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2013006184A true MX2013006184A (es) 2013-07-15

Family

ID=46162794

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006184A MX2013006184A (es) 2010-12-03 2011-11-17 Compuestos de oxazol [5, 4-b]piridin-5-ilo y su uso para el tratamiento de cancer.

Country Status (27)

Country Link
US (1) US8288548B2 (es)
EP (1) EP2646445B1 (es)
JP (1) JP5726321B2 (es)
KR (1) KR101514162B1 (es)
CN (1) CN103221415B (es)
AR (1) AR083868A1 (es)
AU (1) AU2011337033A1 (es)
BR (1) BR112013013282A2 (es)
CA (1) CA2819822C (es)
CL (1) CL2013001518A1 (es)
CO (1) CO6761387A2 (es)
CR (1) CR20130182A (es)
DO (1) DOP2013000116A (es)
EA (1) EA021241B1 (es)
EC (1) ECSP13012653A (es)
ES (1) ES2567271T3 (es)
GT (1) GT201300139A (es)
IL (1) IL226054A0 (es)
MX (1) MX2013006184A (es)
NZ (1) NZ610289A (es)
PE (1) PE20140008A1 (es)
PH (1) PH12013501115A1 (es)
SG (1) SG190680A1 (es)
TW (1) TWI410425B (es)
UA (1) UA109677C2 (es)
WO (1) WO2012074761A1 (es)
ZA (1) ZA201303580B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102279347B1 (ko) 2016-12-15 2021-07-21 한국생명공학연구원 피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
EP3691620B1 (en) 2017-10-05 2022-07-27 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY130363A (en) 2000-02-15 2007-06-29 Sugen Inc "pyrrole substituted 2-indolinone protein kinase inhibitors"
CO5271680A1 (es) * 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
JP2004526727A (ja) * 2001-03-09 2004-09-02 ファイザー・プロダクツ・インク ベンゾイミダゾール抗炎症化合物
EP1554272B1 (en) * 2002-08-09 2006-10-25 Eli Lilly And Company Benzimidazoles and benzothiazoles as inhibitors of map kinase
TWI332003B (en) * 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
AU2005251735A1 (en) 2004-06-04 2005-12-22 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7473784B2 (en) * 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
AU2008282728B2 (en) 2007-08-02 2012-04-19 Amgen Inc. Pl3 kinase modulators and methods of use

Also Published As

Publication number Publication date
CA2819822A1 (en) 2012-06-07
CO6761387A2 (es) 2013-09-30
GT201300139A (es) 2014-04-08
CN103221415B (zh) 2015-06-17
AU2011337033A1 (en) 2013-07-18
PE20140008A1 (es) 2014-01-31
KR20130093140A (ko) 2013-08-21
ES2567271T3 (es) 2016-04-21
JP2013544835A (ja) 2013-12-19
BR112013013282A2 (pt) 2016-09-06
CN103221415A (zh) 2013-07-24
CL2013001518A1 (es) 2013-11-04
UA109677C2 (ru) 2015-09-25
NZ610289A (en) 2015-07-31
EA021241B1 (ru) 2015-05-29
DOP2013000116A (es) 2014-10-31
US20120142724A1 (en) 2012-06-07
EA201390620A1 (ru) 2013-10-30
IL226054A0 (en) 2013-06-27
EP2646445B1 (en) 2016-03-16
CR20130182A (es) 2013-07-09
JP5726321B2 (ja) 2015-05-27
ZA201303580B (en) 2014-12-23
TWI410425B (zh) 2013-10-01
SG190680A1 (en) 2013-07-31
AR083868A1 (es) 2013-03-27
US8288548B2 (en) 2012-10-16
WO2012074761A1 (en) 2012-06-07
KR101514162B1 (ko) 2015-04-21
EP2646445A1 (en) 2013-10-09
ECSP13012653A (es) 2013-08-30
TW201300397A (zh) 2013-01-01
PH12013501115A1 (en) 2013-07-22
CA2819822C (en) 2015-07-21

Similar Documents

Publication Publication Date Title
MY158992A (en) Forms of rifaximin and uses thereof
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
MY160390A (en) Vinyl indazolyl compounds
EP2580213A4 (en) 8- (HETEROARYLMETHYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS
MX355543B (es) Macrociclos peptidomiméticos.
MX2011007930A (es) Conjugados de insulina cristalina.
PH12014501844A1 (en) Peptidomimetic macrocycles
MX368346B (es) Derivados de 1,6- diazabiciclo [3.2,1] octano-7-ona y su uso en el tratamiento de las infecciones bacterianas.
MX340533B (es) Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
CL2011000116A1 (es) Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer.
PH12015501088A1 (en) Dimeric compounds
IL201209A0 (en) Pyrido [2, 3 - d] pyrimidin - 7 - one compounds as inhibitors of pi3k - alpha for the treatment of cancer
IL224863B (en) (3,4,5-trimethoxyphenyl)methanone based compounds and uses thereof for the treatment of cancer
CL2011002812A1 (es) Compuestos derivados de [1,2,4]triazolo[4,3-b]piridazinas; proceso de preparacion; y uso en el tratamiento del cancer a la prostata.
PH12013501115A1 (en) Oxazolo [5, 4 -b] pyridin- 5 -yl compounds and their use for the treatment of cancer
TN2013000231A1 (en) Oxazolo [5, 4 -b] pyridin- 5 -yl compounds and their use for the treatment of cancer
HK1186470A (en) Oxazolo [5, 4 -b]pyridin- 5 -yl compounds and their use for the treatment of cancer
TN2011000545A1 (en) Vinyl indazolyl compounds
UA54671U (en) use of 4,3'-spiro[(2-amino-3-cyano-4,5-dihydropirane[3,2-c]chromen-5-on)-5-methyl-2'-oxyndol] as an anxyolytic
UA57317U (ru) Применение корвитина в качестве средства для лечения острой черепно-мозговой травмы
UA58160U (ru) Применение липофлавона в качесте средства для лечения черепно-мозговой травмы
TN2011000013A1 (en) Amidophenoxyindazoles useful as inhibitors of c-met
UA106224C2 (en) Crystalline insulin-conjugates

Legal Events

Date Code Title Description
FA Abandonment or withdrawal